Table 2. Ex vivo synergy analysis of top 6 drug combinations at clinically achievable concentrations using xenograft model.

Ex vivosynergy analysis of top 6 drug combinations
		Panobinostat (ng/ml)				Romidepsin (ng/ml)
		8		20		80		200
		Fa (%)	CI	Fa (%)	CI	Fa (%)	CI	Fa (%)	CI
Bortezomib (ng/ml)	4.8	98.5 ± 0.6	0.48	97.8 ± 0.1	0.68	96.4 ± 1.9	0.41	96.7 ± 0.7	0.71
	12	97.9 ± 0.1	0.38	96.1 ± 0.1	0.58	97.9 ± 0.1	0.60	97.4 ± 0.5	1.43
Carfilzomib (ng/ml)	12	98.2 ± 0.7	0.35	98.5 ± 0.1	0.79	98.5 ± 0.2	0.81	98.3 ± 0.1	0.62
	30	97.4 ± 0.3	0.26	97.4 ± 0.1	0.64	98.1 ± 0.2	0.29	95.2 ± 2.1	0.52
		Ixabepilone (ng/ml)				Romidepsin (ng/ml)
		30		75		80		200
		Fa (%)	CI	Fa (%)	CI	Fa (%)	CI	Fa (%)	CI
MK1775 (ng/ml)	200	31.9 ± 2.7	0.14	37.3 ± 6.0	0.17	98.9 ± 0.1	0.29	98.5 ± 0.3	0.46
	500	29.6 ± 5.0	0.19	31.4 ± 1.3	0.32	98.5 ± 0.1	0.12	97.8 ± 0.1	0.31